Literature DB >> 6467270

Cardioprotective effects of mioflazine during 1 h normothermic global ischaemia in the canine heart.

W Flameng, R Xhonneux, H Van Belle, M Borgers, A Van de Water, L Wouters, J Wijnants, F Thoné, P Van Daele, P A Janssen.   

Abstract

The cardioprotective effects of mioflazine, a recently developed cardiovascular drug, were investigated in 41 anaesthetised open chest Beagle dogs subjected to 1 h normothermic global myocardial ischaemia. The severity of the model is evidenced by the finding that only one out of 20 control dogs could be weaned from extracorporeal bypass. Oral pretreatment with mioflazine (2.5 mg X kg-1) resulted in complete functional recovery in 17 out of 20 animals. Biochemical analysis of left ventricular biopsies taken before, during and after aortic cross clamping showed a preservation of purines and a better recovery of ATP, ATP/ADP X Pi ratio and energy charge (p less than 0.05) in the pretreated animals. Morphological and cytochemical assessment of the myocardium demonstrated that the ultrastructure of the sarcolemma and its calcium binding capacity is remarkably well preserved in the drug treated animals. These results indicate a strong cardioprotective effect of mioflazine. The biochemical, cytochemical and ultrastructural findings suggest an interaction of the drug with the sarcolemma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6467270     DOI: 10.1093/cvr/18.9.528

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  12 in total

1.  Protection of human, rat, and guinea-pig atrial muscle by mioflazine, lidoflazine, and verapamil against the destructive effects of high concentrations of Ca2+.

Authors:  U Ravens; G S Liu; G Vandeplassche; M Borgers
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

2.  Calcium overload in human giant cell myocarditis.

Authors:  H G Olbrich; G Herrmann; G Vandeplassche; H Michaelis; M Schneider; E Krause; G Kober
Journal:  J Clin Pathol       Date:  1990-08       Impact factor: 3.411

3.  Ultrastructural damage and Ca2(+)-shifts in the canine myocardium subjected to regional incomplete ischemia.

Authors:  G Vandeplassche; F Thoné; C Hermans; M Borgers
Journal:  Basic Res Cardiol       Date:  1990 Jul-Aug       Impact factor: 17.165

4.  Differential cardioprotection with selective inhibitors of adenosine metabolism and transport: role of purine release in ischemic and reperfusion injury.

Authors:  A S Abd-Elfattah; M E Jessen; J Lekven; A S Wechsler
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

5.  Sleep improvement in dogs after oral administration of mioflazine, a nucleoside transport inhibitor.

Authors:  A Wauquier; H Van Belle; W A Van den Broeck; P A Janssen
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  Effects of lidoflazine and mioflazine against potassium and veratrine induced shape changes in isolated rat cardiac myocytes.

Authors:  L Ver Donck; G S Liu; G Vandeplassche; M Borgers
Journal:  Basic Res Cardiol       Date:  1987 Jan-Feb       Impact factor: 17.165

7.  Changes in ultrastructure and Ca2+ distribution in the isolated working rabbit heart after ischemia. A time-related study.

Authors:  M Borgers; L G Shu; R Xhonneux; F Thoné; P Van Overloop
Journal:  Am J Pathol       Date:  1987-01       Impact factor: 4.307

8.  Formation and release of nucleosides in the ischemic myocardium. Is the guinea-pig the exception?

Authors:  H Van Belle; J Wynants; F Goossens
Journal:  Basic Res Cardiol       Date:  1985 Nov-Dec       Impact factor: 17.165

9.  Prevention of the "no reflow" phenomenon in the canine heart by mioflazine.

Authors:  W Flameng; R Xhonneux; J Vanhaecke; A Van de Water; M Suy
Journal:  Basic Res Cardiol       Date:  1985 Jan-Feb       Impact factor: 17.165

10.  Oral pretreatment with mioflazine completely changes the pattern and remarkably prolongs the accumulation of nucleosides in ischemic and reperfused myocardium.

Authors:  H Van Belle; R Xhonneux; W Flameng; J Wynants
Journal:  Basic Res Cardiol       Date:  1986 Jul-Aug       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.